ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9564
-1.15%
Brent Oil
83.48
-2.81%
Bitcoin
57,352.16
-5.36%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Oncorus Inc (ONCR)

  7. Oncorus Inc (ONCR) Noticias

ONCR

Oncorus (ONCR)

Oncorus Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ONCR
FechaHoraFuenteTítuloSímboloCompañía
07/08/202305:52Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ONCROncorus Inc
03/08/202316:00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:ONCROncorus Inc
03/08/202315:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ONCROncorus Inc
26/06/202315:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ONCROncorus Inc
23/06/202305:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ONCROncorus Inc
16/06/202308:21Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ONCROncorus Inc
12/06/202305:45Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ONCROncorus Inc
01/06/202315:05GlobeNewswire Inc.Oncorus Announces Workforce Reduction PlanNASDAQ:ONCROncorus Inc
22/05/202315:05GlobeNewswire Inc.Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
16/05/202315:38Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:ONCROncorus Inc
01/05/202306:36Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:ONCROncorus Inc
24/03/202315:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ONCROncorus Inc
24/03/202306:00GlobeNewswire Inc.Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
14/02/202307:05Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ONCROncorus Inc
04/01/202306:00GlobeNewswire Inc.Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug CandidatesNASDAQ:ONCROncorus Inc
27/12/202217:34Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ONCROncorus Inc
22/12/202205:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:ONCROncorus Inc
30/11/202206:00GlobeNewswire Inc.Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with CancerNASDAQ:ONCROncorus Inc
23/11/202207:00GlobeNewswire Inc.Oncorus to Participate in Upcoming Investor ConferencesNASDAQ:ONCROncorus Inc
18/11/202207:00GlobeNewswire Inc.Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual MeetingNASDAQ:ONCROncorus Inc
07/11/202205:15TipRanksOncorus (ONCR) Gets a Buy from H.C. WainwrightNASDAQ:ONCROncorus Inc
02/11/202215:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ONCROncorus Inc
02/11/202206:00GlobeNewswire Inc.Oncorus Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
01/11/202215:07Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ONCROncorus Inc
07/10/202208:00GlobeNewswire Inc.Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of CancerNASDAQ:ONCROncorus Inc
26/09/202206:00GlobeNewswire Inc.Oncorus to Present at Chardan’s 6th Annual Genetic Medicines ConferenceNASDAQ:ONCROncorus Inc
06/09/202206:00GlobeNewswire Inc.Oncorus to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:ONCROncorus Inc
15/08/202205:15TipRanksH.C. Wainwright Sticks to Its Buy Rating for Oncorus (ONCR)NASDAQ:ONCROncorus Inc
04/08/202206:00GlobeNewswire Inc.Oncorus Reports Second Quarter 2022 Financial Results and Provides Business UpdatesNASDAQ:ONCROncorus Inc
23/06/202206:00GlobeNewswire Inc.Oncorus Appoints Douglas Fambrough to Board of DirectorsNASDAQ:ONCROncorus Inc
 Showing the most relevant articles for your search:NASDAQ:ONCR

Su Consulta Reciente

AMEX
SPY
SPDR S&P 500
SPI
SP500
S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
NVDA
NVIDIA
NYSE
JPM
JP Morgan Chase
COIN
BTCUSD
Bitcoin
USOTC
BNPQY
BNP Paribas (QX)
CCOM
OILBRENT
Brent Oil
USOTC
BASFY
BASF (QX)
USOTC
ADDYY
Adidas (QX)
FX
EURUSD
Euro vs US Dollar
NYSE
DIS
Walt Disney
NYSE
CVX
Chevron
AMEX
XLV
Health Care Select Sector
NASDAQ
GOOGL
Alphabet
USOTC
RHHBY
Roche (QX)
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados